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In a specIalized Medical Thoracic Unit, th~
greater proportion of patients presenting for
treatment will be those who have what we
call obstructive airways disease. This is a
descriptive term, used to describe the physio-
logical impairment which occurs in patients
with asthma, emphysema, andlor chronic
bronchitis.
It shall be my purpose here, therefore, to
deal briefly with a group of drugs com-
monly used in the management of these
patients and also, at times, in the pre-opera-
tive and post-operdtive management of
thoracic surgical patients. Antibiotic therapy
would be a subject in itself, and it is not
proposed to discuss antibiotics at this stage,
therefore, other than to briefly mention
aerosol antibiotic therapy.
BRONCHODILATOR DRUGS
These drugs, when effective, do actively
enlarge the lumen of bronchioles by effects
on bronchiolar smooth muscle. However,
with this initial increase in the size of the
lumen, the patient will also be able more
effectively to cough up secretions, and this, in
turn, will further improve ventilation to the
peripheral portions of the lung. Thus physio-
therapy, and in particular postural drainage,
will often be more successful if the patient
is first given an effective bronchodilator drug.
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Oral Therapy
The oral bronchodilators are relatively
cheap and, in the patients with mild asthma,
they may be very effective. However, they
will be of limited value in the patient with
severe or moderately severe asthma.
Ephedrine is the drug most commonly
prescribed. Ephedrine may cause tremor,
tachycardia, headache, and in elderly men
it may precipitate urinary retention; it will
need to be used with care in patients with
cardiac disease.
In an attempt to reduce some of the side
effects, ephedrine may be combined with a
sedative, such as ephedrobarb, or with amino-
phylline and a sedative, e.g. Amesec, Theo-
sec and Tedral.
Alupent (orciprenaline) and Neo-Epinine
(isoprenaline) tablets are very closely related
to ephedrine chemically and they have similar
side effects. There will, therefore, be little
to gain by giving more than one of these
three drugs at the same time, as to do so
would generally be of no greater therapeutic
effect, but any side effects would be accen-
tuated.
Aminophylline tablets fall into another
class, however, and aminophylline may there-
fore be given in addition to a drug of the
ephedrine group. Aminophylline tablets alone
tend to be less effective than ephedrine. In
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addition, many patients will find they are
unable to tolerate aminophylline because of
nausea, vomiting, or abdominal dispomfort.
In an attempt to overcome this disadvantage,
other aminophylline preparations have been
developed but, like aminophylline itself, they
may also be associated with gastric intoler-
ance. Examples of such preparations are
Choledyl, Androphyllin, Elixophyllin and
Quibron.
Parenteral Therapy
One of the most effective drugs available
for the treatment of acute asthma is adrena-
line. This drug is usually given subcutane-
ously and, in most cases, relief will be ob-
tained in a matter of minutes. The side
effects will be similar to those obtained with
ephedrine but, because parenteral adrenaline
is a more effective drug, it may on occasions
be used where ephedrine has failed.
Where adrenaline has failed to provide
sufficient relief, it is customary to proceed
to parenteral aminophylline. This will be
most effective if given intravenously. While
a single injection may suffice, it will often
be necessary to give the aminophylline by
continuous intravenous drip. Often, a patient
who has been unable to tolerate the drug
orally, will experience no side effects what-
soever when the drug is given parenterally.
Aerosol Therapy
Aerosol therapy is now widely used in the
management of patients with bronchial
asthma. The therapeutic effect approaches
that of parenteral adrenaline and yet, pro-
vided the dosage of the aerosol has been
correctly determined, side effects will be few.
This is due to the fact that a much smaller
dosage of the drug will be required when
the drug is administered in aerosol form.
If aerosol therapy is to be effective, how-
ever, a satisfactory nebuliser must be used.
This should be capable of producing a mist
composed mainly of particles one to three
microns in size. Only small particles of this
size will reach the smaller bronchioles, the
larger particles being deposited progressively
further up the air passages.
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It is not possible here to go into the
different types of nebuliser currently avail-
able, but the drugs commonly used as
aerosol bronchodilators are Neo-Epinine
(isoprenaline) or Alupent (orciprenaline).
Where aerosol therapy has been pre-
scribed, it is important that it be not used
excessively by the patient. With regard to
this, he must be guided by his own doctor.
EXPECTORANTS
Iodides and other expectorants have been
used for many years, in the belief that they
might change the character of the sputum by
thinning the bronchial secretions. While
many clinicians remain firmly convinced that
iodides are of value, it is difficult to prove
that they do, in fact, have any effect at all.
ENZYMES
Because enzymes can attack proteins and
mucin and break them into simpler com-
pounds, enzymes have been used in aerosol
form in the treatment of pulmonary disease.
Enzymes which have been used include
crystalline trypsin, streptodornase, strepto-
kinase, hyaluronidase, and lysozyme. Some
of these enzymes have been available in this
country under various trade names. How-
ever, the results have not been impressive and
the side effects have been relatively high.
Irritation of the eyes and of the respiratory
tract and hypersensitivity reactions have
been reported. For these reasons, the
enzymes have found little place in the clinical
management of patients.
OTHER MUCOLYTIC AGENTS
Mucomyst (acetylcysteine)
In recent years, many favourable reports
have appeared concerning this drug. It is
claimed that it reduces the viscosity of mucus
to a greater extent than do saline solutions,
proteolytic enzymes, or detergents. This is
said to apply to both purulent and non-
purulent bronchial secretions. Although this
would appear to be the most promising drug
available within this group at present, fur-
ther evaluation will be needed.
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Mucomyst is given in aerosol form and
details concerning dosage and administration
are provided with the drug.
Side effects have not been common, but
a few cases of stomatitis, nausea, and occa-
sional rhinorrhea have been reported. The
drug must be used with care in patients with
bronchial asthma, as it may aggravate
"bronchospasm". If the latter should occur,
the patient must immediately be given a
bronchodilator drug.
Ascoxal
Ascoxal is made up of ascorbic acid,
sodium percarbonate, and copper sulphate.
Made up as an aerosol, it has been claimed
to be an effective mucolytic agent. However,
there is as yet little evidence to support
this claim.
DETERGENTS
Alevaire is available in a sterile aqueous
solution for aerosol use, containing a deter-
gent, superinone, with sodium bicarbonate
and glycerine. It is considered by some that
sputum might more easily be mobilized by
use of a detergent such as superinone. While
the drug is apparently non-toxic, recent
reports would suggest that Alevaire delivered
by aerosol is, in fact, no more effective than
simple humidification.
AEROSOL ANTIBIOTIC THERAPY
In most cases, patients with chronic bron-
chial infection will respond satisfactorily to
systemic antibiotic therapy. On occasions,
however, where purulent sputum remains in
spite of intensive therapy by conventional
methods, an aerosol antibiotic may be tried.
It is usual here to use only antibiotics
which the patient is not likely to require,
either orally or parenterally, in the future.
The antibiotics which are more commonly
used in this way are Neomycin, Polymyxin
and Kanamycin.
Unfortunately, where systemic antibiotic
therapy has failed, the results of aerosol
therapy with these drugs will often be dis-
appointing.
STEROID DRUGS
Included under this heading will be cor-
tisone, hydro-cortisone, and derivatives such
as prednisone, prednisolone, triamcinolone,
betamethasone, and methyl-prednisolone.
Some of these drugs will be better known by
their trade names - triamcinolone (Leder-
cort) , betamethasone (Celestone, Betnelan).
In patients with severe bronchial asthma
or related conditions, steroid drugs will, on
occasions, be required as a life-saving
measure. Under these circumstances, it may
be possible to stop the drug within a few
weeks of its commencement. There are, how-
ever, a large group of patients in whom
respiratory disability has progressed to the
stage where they are no longer able to con-
tinue their work, and may have even become
completely bedridden. In some of these cases,
steroid drugs will be employed. However, a
very thorough assessment, preferably with the
aid of pulmonary function tests, should be
made before a patient is committed to long
term steroid therapy. The risks of steroid
therapy are not insignificant, but where other
drugs have proved ineffective, their use will,
on occasions, be warranted.
SUMMARY
In patients with airways obstruction due,
in particular, to asthma or chronic bron-
chitis, steroid drugs will, on occasions, be
required, but the routine bronchodilator
drugs, in particular the aerosol broncho-
dilators, will in general be most effective.
Where bronchodilator therapy has been
prescribed for a patient who is also having
physiotherapy, the patient will often be able
to manage the latter more easily if the
bronchodilator drug has been given initially.
If only an oral bronchodilator has been
used, then this should be taken half an hour
to an hour before the physiotherapy; whereas
if the drug is to be given by aerosol or
parenterally, then the interval between the
drug and the physiotherapy would need to
be only five to ten minutes.
On occasions, where the patient continues
to have difficulty in coughing up thick
secretions, in spite of antibiotic and broncho-
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dilator therapy, a mucolytic agent such as
Mucomyst may be tried. Detergents such as
superinone, on the other hand, would appear
to have no therapeutic effect over and above
that produced by use of a suitable humidifier.
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Expectorants such as potassium iodide orally
continue to be used, but no objective evi-
dence has been produced to show that the
use of iodides does in any way affect the
nature of the bronchial secretions.
